Several randomized clinical trials have established the superior oncological outcomes of the combination of external beam radiotherapy with a high-dose-rate brachytherapy boost (see this link). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: boost, brachytherapy, high, intermediate, progression-free, risk, survival | 1 Comment »
A new review article in the journal Oncology provides us with an overview of the appropriate management of men with “favorable” and “unfavorable” forms of intermediate-risk prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Risk, Treatment | Tagged: favorable, intermediate, Management, risk, unfavorable | Leave a comment »
The EORTC trial 22991 was designed and implemented to compare external beam radiation therapy (EBRT) + short-term androgen deprivation therapy (ADT) to EBRT alone as first-line therapy in patients with intermediate- and high-risk prostate cancer. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: ADT, androgen, deprivation, EBRT, external beam, high, intermediate, radiation, risk | 5 Comments »
From the perspective of the disinterested observer, one of the very least edifying aspects of issues related to the management of prostate cancer has been the nearly 50-year-long “discussion” between the urology community and the radiation oncology community about the most appropriate way(s) to treat localized disease. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: "best", high, intermediate, localized, registry, risk, Treatment, trial | 11 Comments »
The ASCENDE-RT randomized clinical trial demonstrated that the combination of external beam radiation therapy with a brachytherapy boost (EBRT + BT) significantly reduced biochemical progression-free survival. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: boost, brachytherapy, BT, EBRT, external beam, high, intermediate, mortality, outcome, radiation, risk | 3 Comments »
A sophisticated presentation at the annual meeting of the American Society of Clinical Oncology today (on behalf of the West Coast Prostate Cancer “Dream Team”) gave us insights into the the development of neuroendocrine forms of drug-resistant prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: histology, intermediate, neuroendocrine, small cell | 1 Comment »
